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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.006Hepatosplenic T-cell lymphoma (HSTCL) is a rare type of Non-Hodgkin Lymphoma (NHL), grouped under the
mature or peripheral T-cell lymphomas. It is characterised by extranodal infiltration and proliferation of
malignant T-cells within the sinusoids of the liver, sinuses and red pulp of the spleen, and the bone marrow.
The tumour cells express CD2 and CD3, but are CD4, CD5 and CD8 negative and express a clonally restricted
gamma–delta (or less commonly alpha–beta) T-cell receptor. The disease has an aggressive clinical course asso-
ciated with a poor prognosis. We highlight and report three patients from South Africa with HSTCL, all of whom
had hepatosplenomegaly and cytopaenias, and despite being HIV seronegative and immunocompetent, had a
poor outcome, with a mean survival of 7.5 months in the two evaluable patients. This rare entity has not
previously been reported from South Africa and as yet needs to be adequately characterised in a population
where lymphoma is the most common haematological malignancy in adults, and where approximately two
thirds of the adult lymphoma population are HIV seropositive.
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AfricaHepatosplenic T-cell lymphoma (HSTCL) isa rare subset of the peripheral T-cell lym-phomas, with less than one hundred case
reports in the literature. It has been estimated to con-
tribute only 1.4% of all T-cell lymphomas.1 It was
ﬁrst described as a separate entity amongst the periph-
eral/mature T-cell lymphomas in the 1990 REAL
(Revised European American Lymphoma) classiﬁca-
tion.2 It is characterised by malignant T-cell prolifer-
ation with a predisposition for the sinusoids of the
liver, sinuses and red pulp of the spleen, and the
sinuses of the bone marrow; expression of gamma–
delta (cd) (or less commonly alpha–beta) T-cell
receptor (TCR) as part of the malignant T-cell clone;
and a very aggressive clinical course with poor progno-
sis (median overall survival of 11 months),3,4 although
a more recent report suggests improved outcome andsurvival with intensive induction chemotherapy fol-
lowed by early high-dose therapy and hematopoietic
stem cell transplantation.5
HSTCL is more common among young males in
their teenage years and in young adulthood. Approx-
imately 10–20% of patients have a history of immu-
nosuppression, either through treatment for
malignancy (such as in Hodgkin Lymphoma or acute
myeloid leukaemia), inﬂammatory conditions (e.g. inf-
liximab use in inﬂammatory bowel disease), or solid
organ transplants.6,7 The majority of patients have
liver, spleen, and bone marrow involvement at presen-
tation. As a result they tend to be jaundiced, anaemic,
have prominent hepatosplenomegaly, minimal lym-
phadenopathy, and constitutional or ‘B’ symptoms.
Thrombocytopaenia is commonly seen, although this
may be part of a broader pancytopaenia. The cause ofarter 2015
Table 1. Clinical characteristics of the patients with HSTCL.
Patient 1 Patient 2 Patient 3
Presentation
Age at presentation (years) 21 23 42
Gender M M M
Self-reported duration of symptoms 2 weeks 4 months 2 months
Functional status 2 2 4
Fever + + +
Night sweats + + +
Fatigue + + +
LOW/LOA + + +
Abdominal pain/ swelling + + 
Mucous membrane bleeding  + 
Examination
Pallor + + +
Jaundice  + 
Petechiae  + 
Ecchymosis  + 
Lymphadenopathy Shotty generalised Shotty generalised Shotty generalised
Hepatomegaly 8 cm below costal margin 15 cm below costal margin 10 cm below costal margin
Splenomegaly 22 cm below costal margin 15 cm below costal margin 6 cm below costal margin
Management
a. Supportive + + +
b. Specific
Chemotherapy regime:
CHOP + + +
CHOEP +  
CNOP-M +  
FCM + + 
FCR  + 
FCRM  + 
Survival 12 months 3 months <1 month (3 days)
CHOP – cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; CHOEP – CHOP plus etoposide, CNOP-M – cyclophosphamide, novantrone, oncovin, prednisone, methotrexate; FCM –
fludarabine, cyclophosphamide, mitoxantrone; FCR – fludarabine, cyclophosphamide, rituximab; FCRM – FCR plus mitoxantrone.
HEPATOSPLENIC T-CELL LYMPHOMA case reportthe cytopaenias is multifactorial: marrow inﬁltration,
splenic sequestration, haemolytic anaemia, immune-
mediated thrombocytopaenia, or haemophagocytic
syndrome either alone or in combination. Neutropae-
nia is less commonly encountered. Peripheral blood
spill of malignant cells occurs in the leukaemic phaseHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015of the disease.4,7 The immunophenotype of the malig-
nant cells is typically: CD2+, CD3+, cdTCR+,
CD4, CD5, CD8, CD±56.8 An isochromo-
some of the long arm of chromosome 7 (i(7)(q10))
is a recurrent genetic abnormality described in
HSTCL either in isolation or in association with79
Table 2. Laboratory features of patients with HSTCL at CHBAH.
Patient 1 Patient 2 Patient 3
Blood results
White cell count ·109/l 11.21 2.80 44.80 (tumour cells 27.78 · 109/l)
Haemoglobin (g/dl) 10.1 10.1 4.8
Platelets ·109/l 117 29 17
LDH (U/l) 1167 1256 1885
Bilirubin (lmol/l) (total/conjugated) 8/4 133/104 26/21
ALP/GGT (U/l) 93/60 431/228 234/174
ALT/AST (U/l) 13/34 106/249 13/139
INR/PTT (s) 1.33/40.6 1.10/53.1 1.40/49.6
Bone marrow infiltration present + + +
Immunophenotype Flow cytometry IMH Flow cytometry IMH Flow cytometry IMH
CD1a ND  ND ND ND ND
CD2 ND ND + ND + ND
CD3 ND + Equivocal + + +
CD4 ND Occasional + ND Equivocal  ND
CD5 ND    Subgroup + ND
CD7 ND  + ND + ND
CD8 ND     ND
CD16 ND ND ND ND + ND
CD30 ND  ND  + ND
CD34 ND  ND   ND
CD43 ND + ND ND ND ND
CD56 ND Subgroup weakly + ND Weakly +  ND
TdT ND  ND  ND 
EBER ISH ND ND ND  ND ND
Cytogenetics/FISH Failed
Isochrome 7 q + + No result
Trisomy chromosome 8 ND + No result
IMH: immunohistochemistry of the bone marrow trephine/liver biopsy, EBER ISH: Epstein–Barr virus-encoded small RNA in situ hybridisation. ND: not done.
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case report HEPATOSPLENIC T-CELL LYMPHOMAother abnormalities, most notably trisomy 8, with the
combination of these two abnormalities being highly
suggestive of HSTCL.9
There is no standard treatment regime that is
described for this aggressive disease, and reported
results of therapeutic interventions are generally dis-
appointing and have limited efﬁcacy. A variety of che-
motherapeutic regimes have been used; from standardCHOP (cyclophosphamide, hydroxydaunorubicin,
oncovin, prednisone), CHOP-like regimens, purine
analogues, monoclonal antibodies (e.g. alemtuzumab),
platinum-based regimes, ICE (ifosfamide, carboplatin,
etoposide) and IVAC (ifosfamide, etoposide, high-
dose cytarabine).5,10 In the last decade, however, there
have been a number of reports of the successful use of
allogeneic stem cell transplants (SCT), which appearsHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
Fig. 1. Bone marrow aspirate, trephine biopsy and CD3 staining of the three cases. Patient 1 had clumps of tumour cells in the bone marrow
aspirate, and intrasinusoidal marrow infiltration in the trephine biopsy (see arrow). Patient 2 demonstrated extensive sheet-like infiltration of the
bone marrow. Patient 3 exhibited marrow infiltration by a population of tumour cells comprising 50–60% of the cells present. These were
distributed interstitially in the trephine biopsy (see arrows). The tumour cells were all predominantly of intermediate size with a moderate amount
of palely basophilic cytoplasm. All three cases demonstrated a degree of cytoplasmic blebbing or fimbriation. The nuclear:cytoplasmic ratios were
high, and the nuclear chromatin loosely clumped. Only Patient 2 had occasional prominent nucleoli. BMA: Bone marrow aspirate stained with May-
Grnwald Giemsa, high power magnification. BMT: Bone marrow trephine stained with hematoxylin and eosin, high power magnification. CD3:
Immunohistochemical staining for CD3 on the bone marrow trephine biopsies, low power magnification.
LIVER BIOPSY    CD3    Ki-67 
Fig. 2. Liver biopsy from patient 1. Left panel: Infiltration of liver parenchyma by clusters of atypical lymphocytes (see arrows). Centre panel:
Atypical lymphocytes are CD3 positive (see arrow). Right panel: Ki-67 stain approaches 100% in atypical lymphocytes (see arrow). Liver biopsy:
Stained with hematoxylin and eosin at ·40 magnification. CD3: immunohistochemical staining for CD3.
HEPATOSPLENIC T-CELL LYMPHOMA case reportto be the only therapeutic intervention that has
resulted in durable, long term remissions and poten-
tial cure of the disease.5,10,11
There have been no case reports from South
Africa with regard to HSTCL. Chris Hani Baragw-
anath Academic Hospital (CHBAH) is a tertiaryHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015referral centre in Soweto, Johannesburg. More than
two thirds of the adult Non-Hodgkin lymphoma
(NHL) patients seen at this hospital are immunocom-
promised (HIV seropositive) and harbour aggressive
B-cell lymphomas such as diffuse large B-cell
lymphoma, Burkitt lymphoma and plasmablastic81
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Fig. 3. Flow cytometry findings for patient 3. The lymphoid cells were gated by forward light scatter vs side light scatter. The tumour cells are
indicated in blue, and background CD4 and CD8 T-cells in violet and red, respectively. (A) The tumour cells are of intermediate size, are negative for
CD4 and CD8 (B) and strongly positive for CD3 (C). FITC, fluorescein isothiocyanate; PE, phycoerythrin.
Fig. 4. Conventional cytogenetic studies of patient 2 demonstrating an isochromosome of the long arm of chromosome 7 (see arrow) and trisomy of
chromosome 8. Conventional cytogenetic studies using GTW (G-Banding, Trypsin, Wright's stain) were performed, according to standard protocols,
on 24 hour unstimulated bone marrow cultures. The results were interpreted using the ISCN (International System for Human Cytogenetic
Nomenclature, 2009).
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case report HEPATOSPLENIC T-CELL LYMPHOMAlymphoma.12 T-cell lymphomas are less common. We
report three patients with HSTCL, seen over a three
year period – January 2011–December 2013 at
CHBAH.CLINICAL PRESENTATION
Three patients with HSTCL were identiﬁed over a
three-year period (1 January 2011–31 DecemberHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
HEPATOSPLENIC T-CELL LYMPHOMA case report
2013) at the adult Clinical Haematology unit, Depart-
ment of Medicine, Chris Hani Baragwanath Aca-
demic Hospital. All three of these patients were
male, of black ethnicity, and presented at a mean
age of 29 years (range: 21–42 years). All were HIV
seronegative, with no other history or evidence of
immunosuppression. A summary of the clinical
features of these patients at presentation is depicted
in Table 1. Of note is that all the patients had
constitutional symptoms, hepatosplenomegaly and
cytopaenias, but no signiﬁcant lymphadenopathy.
The laboratory features at presentation for the
patients are summarised in Table 2 and depicted in
Figs. 1–4. All the patients showed abnormalities of
their blood counts, with patient 3 presenting in a
leukaemic phase of the disease. All the patients had
malignant inﬁltration of their bone marrow. In
addition, patient 1 had conﬁrmed hepatic inﬁltration
on liver biopsy with CD3+ tumour cells (liver biopsy
was performed as his ﬁrst bone marrow investigation
did not yield a diagnosis, due to subtle inﬁltration).DISCUSSION AND CONCLUSIONS
HSTCL is a rare subset of NHL. There are no
reports in the literature of this entity being described
in South Africa, despite lymphoma being the most
common haematological malignancy in adults (the
possibility of under-reporting of this entity cannot
be excluded). The clinical presentation in the three
patients seen at CHBAH is similar to that reported
in the literature, with hepatosplenomegaly, minimal
lymphadenopathy, constitutional symptoms, and
cytopaenias. All patients had inﬁltration of bone
marrow, spleen, and liver at presentation, although
the degree of inﬁltration varied. Patient 3 presented
in the leukaemic phase of the disease with evidence
of disease in the peripheral blood, more profound
cytopaenias, and a very poor performance status
(PS = 4).
In addition to supportive care, the patients
received combination chemotherapy, as indicated in
Table 1. Despite the use of a number of different
combination chemotherapy regimens in patients 1
and 2, neither of the patients achieved a complete
remission and both died of refractory disease, with a
mean survival of 7.5 months. Patient 3 presented inHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015the leukaemic phase of the disease and demised
shortly after initiating chemotherapy and was thus
inevaluable. None of the three patients were consid-
ered for or were candidates for SCT.
Prior to the use of allogeneic SCT, the literature
shows the limited efﬁcacy and uniformly poor
outcome of patients treated with a variety of chemo-
therapeutic interventions.10 However, recent reports
suggest a better outcome with SCT,5,10,11 particularly
with the use of intensive induction chemotherapy fol-
lowed by early high-dose therapy and hematopoietic
SCT.5
Clinicians, including haematologists, oncologists
and pathologists need to be aware of this rare, aggres-
sive form of NHL, so that a diagnosis can be readily
established and the patient managed aggressively, with
early consideration of SCT – the only potentially
curative intervention in patients with HSTCL. Addi-
tionally, a multi-centred approach is advised, with
pooling of patient data and the use of a uniform ther-
apeutic approach, in order to explore and optimise the
management of patients with this rare form of T-cell
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